Results 41 to 50 of about 20,710 (242)

UMOD Genotype and Clinical Outcomes in Heart Failure Patients Treated with Loop Diuretics: A UK Biobank Pharmacogenetic Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Uromodulin (UMOD) regulates tubular sodium handling and modulates NKCC2, the molecular target of loop diuretics (LD). Although UMOD variants have been associated with blood pressure and hypertension, their pharmacogenetic relevance in heart failure (HF) remains unknown.
Reinhold Kreutz, Pimrapat Gebert, Jingwen Luo, Paraskevi Tassopoulou, Juliane Bolbrinker, Antonios Douros   +5 more
wiley   +1 more source

Tripchlorolide attenuates β-amyloid generation by inducing NEP activity in N2a/APP695 cells

Translational Neuroscience, 2021
Alzheimer’s disease (AD) is a neurodegeneration disease. The previous work from our research group demonstrated the neuroprotective effects of tripchlorolide (T4) in AD animal models.
Zeng Yuqi, Li Yongkun, Shen Hui, Lin Nan, Zhang Jian   +4 more
doaj   +1 more source

Effects of BNP and Sacubitrilat/Valsartan on Atrial Functional Reserve and Arrhythmogenesis in Human Myocardium

Frontiers in Cardiovascular Medicine, 2022
BackgroundAlthough the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan started a new era in heart failure (HF) treatment, less is known about the tissue-level effects of the drug on the atrial myocardial functional reserve and ...
Uwe Primessnig, Uwe Primessnig, Uwe Primessnig, Peter M. Deißler, Peter M. Deißler, Paulina Wakula, Paulina Wakula, Khai Liem Tran, Khai Liem Tran, Felix Hohendanner, Felix Hohendanner, Felix Hohendanner, Dirk von Lewinski, Florian Blaschke, Florian Blaschke, Christoph Knosalla, Christoph Knosalla, Volkmar Falk, Volkmar Falk, Volkmar Falk, Burkert Pieske, Burkert Pieske, Burkert Pieske, Burkert Pieske, Herko Grubitzsch, Herko Grubitzsch, Frank R. Heinzel, Frank R. Heinzel   +27 more
doaj   +1 more source

Enhancing Evidence Generation by Linking Randomized Clinical Trials to Real‐World Data: The INVESTED‐Medicare Linkage Study

Clinical Pharmacology &Therapeutics, EarlyView.
Real‐world evidence (RWE) derived from real‐world data (RWD) can complement randomized controlled trials (RCTs), yet the validity of RWD relative to RCT data remains insufficiently characterized. We obtained post hoc consent and linked individual participant data from the US‐based INVESTED trial (2016–2019) with Medicare fee‐for‐service claims (2012 ...
Hanseul Cho, HoJin Shin, Mehdi Najafzadeh, Brian Claggett, Janinne Ortega‐Montiel, Jun Liu, Julie M. Paik, Narlina F. Lalani, Marie C. Bradley, John Concato, Scott D. Solomon, Orly Vardeny, Elisabetta Patorno   +12 more
wiley   +1 more source

Upregulation of neprilysin as a potential therapeutic approach in Alzheimer's disease [PDF]

, 2006
SUMMARY Alzheimer’s disease (AD) is the major cause of dementia and cognitive impairments among older people and affects more than 30% of the population above 85 years of age.
Poirier, Raphaël
core   +3 more sources

Phosphodiesterase 9 Inhibition Combined With Valsartan and With Sacubitril/Valsartan in Experimental Ovine Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background LCZ696 (sacubitril/valsartan) antagonizes the renin–angiotensin system while simultaneously augmenting the natriuretic peptides (NPs). Inhibition of phosphodiesterase 9 inhibition (PDE9i), which hydrolyses NP‐generated cGMP may be a more ...
Nicola J. A. Scott, Christopher J. Charles, Timothy C. R. Prickett, Christopher M. Frampton, A. Mark Richards, Miriam T. Rademaker   +5 more
doaj   +1 more source

Cardiac Resynchronization as an Enabler of ARNI Efficacy: Insights From a Real-World Cohort. [PDF]

J Arrhythm
CRT provides the mechanical substrate that enables sacubitril/valsartan to maximize reverse remodeling. In this real‐world cohort, ARNI therapy was associated with greater improvement in left ventricular function and fewer clinically validated device‐detected HF events, particularly among CRT responders, supporting a synergistic interaction between ...
Santoro A, Spaccaterra L, Collantoni M, Baiocchi C, Natali BM, Lunghetti S, Pagliaro A, Manetti N, Morrone F, Fineschi M, Palazzuoli A.   +10 more
europepmc   +2 more sources

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

Neprilysin inhibitors for the treatement of heart failure

, 2023
Neprilysin inhibitors, such as sacubitril/valsartan, are a class of drugs used in the treatment of heart failure with reduced ejection fraction (HFrEF). They work by inhibiting the enzyme neprilysin, which increases the levels of beneficial peptides like
Abo Asalh, Majd
core  

Novel aspect of neprilysin in kidney fibrosis via ACSL4‐mediated ferroptosis of tubular epithelial cells

MedComm, 2023
Although inhibition of neprilysin (NEP) might be a therapeutic strategy with the potential to improve the outcome of chronic kidney disease (CKD), the versatile function of NEP with its mechanism remains obscure in kidney fibrosis. In the study, we found
Weijing Lai, Rongshuang Huang, Bo Wang, Min Shi, Fan Guo, Lingzhi Li, Qian Ren, Sibei Tao, Ping Fu, Liang Ma   +9 more
doaj   +1 more source